Park Ha Biological Technology Co., Ltd. Announces Pricing of $4.8 Million Initial Public Offering
Park Ha Biological Technology, a Chinese skincare company, announced the pricing of its Initial Public Offering (IPO) of 1,200,000 ordinary shares at $4.00 per share, expecting to raise $4.8 million in gross proceeds. The shares will trade on the Nasdaq Capital Market under symbol PHH starting December 27, 2024.
The underwriters have a 45-day option to purchase up to 180,000 additional shares. The IPO proceeds will fund expansion of directly-owned stores in China, purchase of product patents for proprietary products, and acquisition of ingredient suppliers to reduce production costs. Dawson James Securities and D. Boral Capital are serving as underwriters for the offering, which is expected to close around December 30, 2024.
Park Ha Biological Technology, un'azienda cinese di skincare, ha annunciato il prezzo della sua Offerta Pubblica Iniziale (IPO) di 1.200.000 azioni ordinarie a $4.00 per azione, prevedendo di raccogliere $4,8 milioni in ricavi lordi. Le azioni saranno negoziate sul Mercato Capitale Nasdaq con il simbolo PHH a partire dal 27 dicembre 2024.
Gli underwriter hanno un'opzione di 45 giorni per acquistare fino a 180.000 azioni aggiuntive. I proventi dell'IPO finanzieranno l'espansione dei negozi a propriet脿 diretta in Cina, l'acquisto di brevetti di prodotto per prodotti proprietari e l'acquisizione di fornitori di ingredienti per ridurre i costi di produzione. Dawson James Securities e D. Boral Capital stanno fungendo da underwriter per l'offerta, che si prevede si chiuder脿 intorno al 30 dicembre 2024.
Park Ha Biological Technology, una empresa china de cuidado de la piel, anunci贸 el precio de su Oferta P煤blica Inicial (IPO) de 1.200.000 acciones ordinarias a $4.00 por acci贸n, esperando recaudar $4.8 millones en ingresos brutos. Las acciones se negociar谩n en el Mercado de Capitales Nasdaq bajo el s铆mbolo PHH a partir del 27 de diciembre de 2024.
Los suscriptores tienen una opci贸n de 45 d铆as para comprar hasta 180.000 acciones adicionales. Los ingresos de la IPO financiar谩n la expansi贸n de tiendas de propiedad directa en China, la compra de patentes de productos para productos propios y la adquisici贸n de proveedores de ingredientes para reducir los costos de producci贸n. Dawson James Securities y D. Boral Capital est谩n actuando como suscriptores de la oferta, que se espera que cierre alrededor del 30 de diciembre de 2024.
Park Ha Biological Technology, 欷戧淡鞚 鞀ろ偍旒鞏 須岇偓, 1,200,000欤茧ゼ 欤茧嫻 $4.00鞐 靸侅灔頃橂姅 旮办梾瓿店皽(滨笔翱) 臧瓴╈潉 氚滍憸頃橂┌ $4.8 氚彪鞚 齑濎垬鞚奠潉 旮半寑頃橁碃 鞛堨姷雼堧嫟. 鞚 欤检嫕鞚 雮橃姢雼 鞛愲掣鞁滌灔鞐 PHH 旮绊樃搿 2024雲 12鞗 27鞚茧秬韯 瓯半灅霅 鞓堨爼鞛呺媹雼.
鞚胳垬鞐呾泊電 45鞚 鞚措偞鞐 斓滊寑 180,000欤检潣 於旉皜 毵れ瀰 鞓奠厴鞚 臧歆瓿 鞛堨姷雼堧嫟. IPO 靾橃澋鞚 欷戧淡 雮 歆侅榿 毵れ灔 頇曥灔, 霃呾爯 鞝滍拡鞐 雽頃 鞝滍拡 韸鬼棃 甑Г 氚 靸濎偘 牍勳毄 鞝堦皭鞚 鞙勴暅 鞗愲 瓿店笁鞐呾泊 鞚胳垬毳 歆鞗愴暊 瓴冹瀰雼堧嫟. Dawson James Securities鞕 D. Boral Capital鞚 鞚 鞝滌晥鞚 鞚胳垬鞐呾泊搿 頇滊彊頃橁碃 鞛堨溂氅, 鞝滌晥鞚 2024雲 12鞗 30鞚缄步鞐 毵堦皭霅 瓴冹溂搿 鞓堨儊霅╇媹雼.
Park Ha Biological Technology, une entreprise chinoise de soins de la peau, a annonc茅 le prix de son Introduction en Bourse (IPO) de 1.200.000 actions ordinaires 脿 4,00 $ par action, s'attendant 脿 lever 4,8 millions de $ de recettes brutes. Les actions seront cot茅es sur le Nasdaq Capital Market sous le symbole PHH, 脿 partir du 27 d茅cembre 2024.
Les souscripteurs ont une option de 45 jours pour acheter jusqu'脿 180.000 actions suppl茅mentaires. Les recettes de l'IPO financeront l'expansion des magasins d茅tenus directement en Chine, l'achat de brevets de produits pour des produits de marque, et l'acquisition de fournisseurs d'ingr茅dients afin de r茅duire les co没ts de production. Dawson James Securities et D. Boral Capital servent d'interm茅diaires pour l'offre, qui devrait se cl么turer aux alentours du 30 d茅cembre 2024.
Park Ha Biological Technology, ein chinesisches Hautpflegeunternehmen, hat den Preis f眉r sein Initial Public Offering (IPO) von 1.200.000 Stammaktien zu je 4,00 $ bekannt gegeben und erwartet, 4,8 Millionen $ an Bruttoerl枚sen zu erzielen. Die Aktien werden ab dem 27. Dezember 2024 unter dem Symbol PHH am Nasdaq Capital Market gehandelt.
Die Emissionsbanken haben eine 45-t盲gige Option, bis zu 180.000 zus盲tzliche Aktien zu kaufen. Die Erl枚se aus dem IPO werden zur Finanzierung des Ausbaus von eigenen L盲den in China, zum Kauf von Produktpatenten f眉r eigene Produkte und zum Erwerb von Lieferanten von Zutaten verwendet, um die Produktionskosten zu senken. Dawson James Securities und D. Boral Capital fungieren als Emissionsbanken f眉r das Angebot, das voraussichtlich rund am 30. Dezember 2024 abgeschlossen wird.
- IPO will raise $4.8 million in gross proceeds
- Nasdaq Capital Market listing approval secured
- Firm commitment basis offering structure
- Strategic use of proceeds for store expansion and vertical integration
- Relatively small IPO size might limit market liquidity
- Potential dilution from underwriters' option for additional 180,000 shares
Insights
Park Ha Biological Technology's IPO reveals a strategic market entry with notable implications for the skincare industry. The
The firm commitment underwriting structure, backed by Dawson James Securities and D. Boral Capital, adds credibility to the offering. The 45-day overallotment option for an additional
However, investors should note the relatively small float of 1.2 million shares, which could lead to significant price volatility post-listing. The timing of the IPO, amid challenging market conditions for Chinese companies listing in the US, warrants careful consideration of geopolitical and regulatory risks.
This IPO represents a calculated entry into the premium skincare market segment, with Park Ha's focus on private label development aligning with growing consumer demand for personalized beauty solutions. The company's three-pronged expansion strategy targets key industry pain points:
- Retail footprint expansion to enhance direct consumer engagement
- Patent acquisition to build proprietary technology moat
- Supply chain optimization through vertical integration
The Chinese skincare market's robust growth trajectory, coupled with increasing consumer sophistication and preference for premium products, provides a favorable backdrop for Park Ha's expansion. The franchise alliance model suggests potential for rapid scalability with controlled capital expenditure. The decision to list on Nasdaq rather than domestic exchanges indicates ambitions for international brand recognition and access to global capital markets.
Wuxi, China, Dec. 26, 2024 (GLOBE NEWSWIRE) -- Park Ha Biological Technology Co., Ltd. (the "Company"), a company focused on developing private skincare labels, direct skincare product sales, and franchise alliance promotions, today announced the pricing of its initial public offering (the "Offering") of 1,200,000 ordinary shares at a public offering price of
The Company expects to receive aggregate gross proceeds of
Net proceeds from the Offering will be used for (i) expanding the scale of directly-owned stores in the PRC; (ii) purchasing existing product patents to develop proprietary products; and (iii) acquiring ingredient suppliers to reduce production costs over the long term.
The Offering is being conducted on a firm commitment basis. Dawson James Securities, Inc. and D. Boral Capital LLC acted as underwriters for the Offering (the 鈥淯nderwriters鈥). Ortoli Rosenstadt LLP is acting as U.S. securities counsel to the Company, and Hunter Taubman Fischer & Li LLC is acting as U.S. securities counsel to the Underwriters in connection with the Offering.
A registration statement on Form F-1 relating to the Offering was filed with the U.S. Securities and Exchange Commission (the "SEC") (File Number: 333-281783) and was declared effective by the SEC on December 20, 2024. The Offering is being made only by means of a prospectus, forming a part of the registration statement. Copies of the prospectus relating to the Offering may be obtained, when available, from Dawson James Securities, Inc. by standard mail to Dawson James Securities, Inc., 101 N. Federal Highway Suite 600 Boca Raton, Florida 33432, or by email at , or by telephone at +1(561)-391-5555; or from D. Boral Capital LLC by standard mail to D. Boral Capital LLC, 590 Madison Ave 39th Floor, New York, NY 10022, or by email at , or by telephone at +1(212)-970-5150. In addition, copies of the prospectus relating to the Offering may be obtained via the SEC's website at .
Before you invest, you should read the prospectus and other documents the Company has filed or will file with the SEC for more information about the Company and the Offering. This press release has been prepared for informational purposes only and shall not constitute an offer to sell, or the solicitation of an offer to buy any of the Company's securities, nor shall there be any offer, solicitation or sale of any of the Company's securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.
About Park Ha Biological Technology Co., Ltd.
Established in 2016, Park Ha Biological Technology Co., Ltd. is primarily engaged in developing its private skincare label, direct skincare products sales and franchise alliances promotions under the proprietary brand 鈥淧ark Ha鈥, with a commitment to providing cost-effective solutions to skin problems and improving the confidence of women in need of skin treatment. As of April 30, 2024, the Company has two directly operated stores and 43 franchisees, of which 41 and two operate under the store name 鈥淧ark Ha鈥 and 鈥淕eni鈥 respectively, in China. As part of its value-added service for the products, the Company offers 鈥渓ight beauty experience鈥, a quick complimentary after-sales beauty service performed in the directly-operated stores and franchise stores. For more information, please visit the Company鈥檚 website: .
Forward-Looking Statements
Certain statements in this announcement are forward-looking statements, including, but not limited to, the Company's proposed Offering. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs, including the expectation that the Offering will be successfully completed. Investors can find many (but not all) of these statements by the use of words such as 鈥渁pproximates,鈥 鈥渂elieves,鈥 鈥渉opes,鈥 鈥渆xpects,鈥 鈥渁nticipates,鈥 鈥渆stimates,鈥 鈥減rojects,鈥 鈥渋ntends,鈥 鈥減lans,鈥 鈥渨ill,鈥 鈥渨ould,鈥 鈥渟hould,鈥 鈥渃ould,鈥 鈥渕ay鈥 or other similar expressions in this prospectus. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's registration statement and other filings with the SEC.
For more information, please contact:
Park Ha Biological Technology Co., Ltd.
Investor Relations Department
Email:
Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email:
FAQ
What is the IPO price and size for Park Ha Biological Technology (PHH)?
When will PHH stock start trading on Nasdaq?
How will Park Ha Biological Technology use its IPO proceeds?
What is the underwriters' option in the PHH IPO?
When is the expected closing date for Park Ha Biological Technology's IPO?
